Citadel Advisors
BBNX

Citadel Advisors’s Beta Bionics BBNX Stock Holding History

Citadel Advisors’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$522K Sell
52,142
-268,738
-84% -$3.97M ﹤0.01% 9195
2025
Q4 		$9.78M Buy
+320,880
New +$8.57M ﹤0.01% 3283
2025
Q3 		– Sell
-539,963
Closed -$7.86M – 14518
2025
Q2 		$7.86M Sell
539,963
-406,387
-43% -$5.75M ﹤0.01% 3378
2025
Q1 		$11.6M Buy
+946,350
New +$17.6M ﹤0.01% 2663

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's BBNX Position: Q1 2026 in Review

Citadel Advisors reduced its Beta Bionics (BBNX) stake by 84% in Q1 2026, selling an estimated $3.97M and leaving 52,142 shares worth $522K. The position accounts for ﹤0.01% of the portfolio, ranked #9195.

Citadel Advisors first reported a position in BBNX in Q1 2025 and has held it in 4 quarters since. The position peaked at $11.6M in Q1 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Citadel Advisors held 52,142 shares of Beta Bionics worth $522K as of Q1 2026.
  • Citadel Advisors sold 268,738 Beta Bionics shares in Q1 2026, an estimated $3.97M.
  • Beta Bionics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9195 holding.
  • Citadel Advisors first reported a position in Beta Bionics in Q1 2025 and has held it in 4 quarters since.
  • Citadel Advisors's Beta Bionics position peaked at $11.6M in Q1 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.